PUBLIC COMPANY
save$CCCCC4 Therapeutics, Inc.
$CCCCWatertown, MA, USupdated 18d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- phase1Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
- phase2A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- phase1A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
- phase1A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
Insider activity
source: SEC Form 4routine RSU / option mechanics (2)
- Apr 1, 26grantGROGAN DONNA ROY · director5,370 sh
- Apr 1, 26grantAnderson Kenneth Carl · director4,259 sh
🐶 Hiring Signal
News
- Biotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challengeA group of 61 biopharma companies, executives and investors has filed an amicus brief in support of the FDA in an ongoing case brought by Louisiana meant to remove access to the abortion pill mifep…fiercebiotech · 27d ago
Data sources
last refreshed 12m ago
Found something off?
comments(0)
5-min edit window · permanent after that